Travere plans CRO retirement, expands CMO role

Travere Therapeutics announced that Chief Research Officer William Rote, Ph.D. plans to retire from the company effective February 17, 2027, which marks the 10-year anniversary of his employment.

Rhea-AI Filing Summary

Travere Therapeutics announced that Chief Research Officer William Rote, Ph.D. plans to retire from the company effective February 17, 2027, which marks the 10-year anniversary of his employment. He is expected to remain in his current role until that date and support a smooth transition.

The responsibilities currently overseen by Dr. Rote are expected to be assumed by Jula Inrig, M.D., the company’s Chief Medical Officer. Effective July 1, 2026, Dr. Inrig will be named Executive Vice President, Head of Research & Development and Chief Medical Officer. Travere also expects to enter into a consulting arrangement with Dr. Rote following his retirement to maintain access to his expertise.

Insights

Biopharma governance analyst

Travere discloses a planned R&D leadership transition with long lead time and continuity.

Travere Therapeutics outlines an orderly shift in R&D leadership as Chief Research Officer William Rote plans to retire effective February 17, 2027. He is expected to stay in role until retirement and assist with transitioning responsibilities.

R&D oversight is expected to consolidate under Jula Inrig, M.D., who becomes Executive Vice President, Head of Research & Development and Chief Medical Officer on July 1, 2026. The planned consulting arrangement with Dr. Rote aims to preserve institutional knowledge, while the company notes typical forward-looking risks around human capital and business needs.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Retirement effective date: February 17, 2027 Title change effective date: July 1, 2026 Employment anniversary: 10 years +1 more

4 metrics

Retirement effective date February 17, 2027 Planned retirement date for Chief Research Officer William Rote

Title change effective date July 1, 2026 Effective date for Jula Inrig’s expanded role as EVP, Head of R&D and CMO

Employment anniversary 10 years Retirement date coincides with 10-year employment anniversary for William Rote

Filing reference date June 12, 2026 Date when William Rote provided notice of his intention to retire

Key Terms

Chief Research Officer, Chief Medical Officer, Executive Vice President, Head of Research & Development, forward-looking statements, +1 more

5 terms

Chief Research Officer financial

"William Rote, Ph.D., Chief Research Officer of the Company, provided notice"

Chief Medical Officer financial

"Jula Inrig, M.D., the Company's Chief Medical Officer"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Executive Vice President, Head of Research & Development financial

"Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer"

forward-looking statements regulatory

"This report contains “forward-looking statements” as that term is defined"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Risk Factors regulatory

"including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Travere Therapeutics (TVTX) announce in R&D?

Travere Therapeutics announced that Chief Research Officer William Rote, Ph.D., plans to retire effective February 17, 2027. His responsibilities are expected to transition to Chief Medical Officer Jula Inrig, M.D., who will also become Executive Vice President, Head of Research & Development on July 1, 2026.

When will Travere Therapeutics’ Chief Research Officer retire?

Chief Research Officer William Rote, Ph.D., intends to retire from Travere Therapeutics effective February 17, 2027. This date aligns with the 10-year anniversary of his employment, and he is expected to remain in his current position until then to support a smooth leadership transition.

What new role will Jula Inrig, M.D., assume at Travere Therapeutics (TVTX)?

Effective July 1, 2026, Jula Inrig, M.D., will be named Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics. She is expected to assume responsibilities currently overseen by Chief Research Officer William Rote, Ph.D., as part of the planned transition.

Will Travere Therapeutics keep working with William Rote after his retirement?

Travere Therapeutics expects to enter into a consulting arrangement with William Rote, Ph.D., following his retirement. This planned consulting role is intended to provide continued access to his expertise and support ongoing research and development activities after he leaves full-time employment with the company.

What forward-looking statements are highlighted in this Travere Therapeutics 8-K?

The report identifies forward-looking statements about the planned retirement of William Rote, timing of the leadership transition, changes to Jula Inrig’s role, and the expectation of a consulting agreement. Travere notes these involve risks related to human capital, business needs, and other uncertainties discussed in its periodic filings.

How does Travere Therapeutics describe the risks around this leadership transition?

Travere Therapeutics notes that risks related to human capital and the company’s business needs and resources could affect the outcomes described. It emphasizes that forward-looking statements about retirement timing, role changes, and consulting arrangements may differ from expectations, referring investors to detailed Risk Factors in its Form 10-K and Form 10-Q.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:34 PM Learn about SEC filing dates

0001438533false00014385332026-06-122026-06-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

___________________________

Current Report

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2026

___________________________

TRAVERE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________

Delaware

001-36257

27-4842691

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3611 Valley Centre Drive, Suite 300

San Diego, CA 92130

(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

TVTX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the “Retirement Date”), the 10 year anniversary of his employment with the Company.

It is expected that Dr. Rote will continue to serve in his current position through the Retirement Date and will assist in the transition of his responsibilities. The responsibilities currently overseen by Dr. Rote are expected to be assumed by Jula Inrig, M.D., the Company's Chief Medical Officer. Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.

The Company expects to enter into a consulting arrangement with Dr. Rote to enable continued access to Dr. Rote following his retirement.

Forward-Looking Statements

This report contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements and expectations regarding the planned retirement of Dr. Rote and the planned changes to Dr. Inrig’s title and responsibilities, and the expected timing thereof; and the expectation to enter into a consulting agreement with Dr. Rote. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to human capital and the Company’s business needs and resources. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRAVERE THERAPEUTICS, INC.

Dated: June 16, 2026

By:

/s/ Eric Dube

Name:

Eric Dube

Title:

Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.7 KB